bioAffinity Technologies
San Antonio, Texas, United States · Biotechnology, Health Care, Health Diagnostics
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) b
Key facts
- Headquarters
- San Antonio, Texas, United States
- Employees
- 34
- Industries
- Biotechnology, Health Care, Health Diagnostics
- Status
- Public (BIAF)
- Website
- bioaffinitytech.com
- Company page
Recent activity at bioAffinity Technologies
- : SEC 8-K (8.01): On October 15, 2026, bioAffinity Technologies, Inc. announced through a press release that it will sponsor a Learning Theater presentation at CHEST 2026, focusing on the role of its product CyPath Lung® in lung cancer risk stratification and managing pulmonary nodules for high-risk patients. This presentation will include discussions on the company's positive research data related to a new test that measures asthma and COPD-related lung inflammation and drug-related receptors. The event highlights the strategic importance of CyPath Lung® in the oncology arena and demonstrates the company's commitment to advancing pulmonary health treatments.
- : SEC 8-K (8.01): On October 13, 2026, bioAffinity Technologies, Inc. announced via a press release its participation in CHEST 2026, where they will present new data on their investigational sputum-based tests. These tests aim to characterize lung inflammation and identify multiple protein biomarkers relevant for asthma and COPD therapies. The Company specified that these tests are not FDA approved or available for clinical use, indicating they are still in development. This announcement highlights the Company's ongoing research efforts and potential future applications in respiratory health.
- : SEC 8-K (1.01): On October 8, 2026, bioAffinity Technologies, Inc. entered into a material definitive agreement in the form of a securities purchase agreement with an institutional investor. Under this agreement, the Company agreed to issue and sell 116,545 shares of its common stock at an offering price of $6.122 per Share, along with pre-funded warrants allowing the purchase of up to 536,836 additional shares of common stock at $6.115 per warrant. This agreement enhances the Company's capital structure and supports its ongoing business needs, reflecting strategic growth initiatives. The successful completion of this transaction indicates investor confidence in the Company’s market positioning and future prospects.
- : SEC 8-K (8.01): On October 8, 2026, bioAffinity Technologies, Inc. announced through a press release that the Japan Patent Office has issued a Notice of Allowance for a patent concerning their innovative method of predicting the likelihood of lung cancer, utilizing the CyPath® Lung test designed for early-stage lung cancer detection. This patent is a significant milestone for the company as it bolsters their intellectual property portfolio and may enhance their market position in cancer diagnostics. The grant of this patent represents potential future revenue streams and establishes the company's credibility in the biomedical field, particularly in oncological assessments.
- : SEC 8-K (8.01): On October 6, 2026, bioAffinity Technologies, Inc. announced through a press release that sales of its CyPath® Lung test for lung cancer increased by over 100% through the third quarter of 2026 compared to the same period in 2025. This significant growth in sales reflects the continued clinical adoption of the Company's noninvasive test for assessing lung cancer, indicating strong market demand and potential for further expansion. The announcement underscores the positive trajectory of bioAffinity's operations and its commitment to enhancing cancer diagnostics.
- : bioAffinity Technologies and AvMEDICAL Form Distribution Partnership to Expand Access to Lung Cancer Testing for Veterans.
- : SEC 8-K (8.01): On September 30, 2026, bioAffinity Technologies, Inc. announced through a press release that it has successfully delivered the first joint exhibition of CyPath® Lung as part of its newly established distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB). This event was presented to over 300 physicians, healthcare professionals, and VA leaders during the National Association of Veterans’ Research and Education Foundations (NAVREF) Annual Conference held in Arlington, Virginia. This strategic partnership is expected to enhance the reach of bioAffinity's innovative health solutions within the veteran community, reflecting a significant step in expanding their market presence and engagement.
- : SEC 8-K (8.01): On September 22, 2026, bioAffinity Technologies, Inc. issued a press release regarding its participation in the 2026 NAVREF Annual Conference. The company is presenting two posters that focus on its noninvasive lung cancer diagnostic technology, CyPath® Lung. These presentations aim to demonstrate the technology's application in clinical practice as well as ongoing research efforts evaluating its effectiveness in veteran and military populations. This engagement at a notable conference illustrates the company's commitment to advancing cancer diagnostics and expanding its visibility within the medical community.
- : SEC 8-K (8.01): On September 17, 2026, bioAffinity Technologies, Inc. announced in a press release that it has been granted a patent by the Hong Kong Intellectual Property Department for its proprietary technology designed to predict the likelihood of lung cancer. This technology utilizes flow cytometry and fluorescent markers to analyze cell populations in sputum, marking a significant advancement in the company's diagnostic capabilities. The patent potentially positions the company for enhanced market opportunities in cancer diagnostics and treatment, which could have strategic implications for its growth and development in the healthcare sector.
- : SEC 8-K (7.01):
bioAffinity Technologies funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Post-IPO Equity | $4.0M |
| Aug 2024 | Venture | $450K |
| Aug 2024 | Venture | $1.3M |
| Mar 2024 | Seed | $2.6M |
| Sep 2022 | Post-IPO Equity | $7.7M |
Leadership
- Stuart Diamond, Chairman of Audit Committee, Board of Director
- Maria Zannes, Chief Executive Officer, President and Director
- Dallas, Vice President, US Sales
- Xavier, Chief Operating Officer
- J. Michael Edwards, Chief Financial Officer
- David Elzi, Vice President
Verified email and direct lines for bioAffinity Technologies’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
bioAffinity Technologies files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
bioAffinity Technologies in the news
- bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Business Wire (Aug 13, 2026)
- bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 - Business Wire (Aug 20, 2026)
- bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history - Yahoo Finance UK (Mar 31, 2023)
- Nasdaq cancels hearing after a biotech company regains compliance - Stock Titan (Sep 09, 2026)
- bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm - Business Wire (Oct 08, 2026)
- bioAffinity Technologies, Inc. (BIAF) Company Profile & Facts - Yahoo! Finance Canada (Aug 22, 2022)
- bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Business Wire (Sep 03, 2026)
- bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Business Wire (Oct 09, 2026)
Companies similar to bioAffinity Technologies
- Cerenome · Biotechnology, Health Care, Health Diagnostics, Therapeutics
- Inoviq Ltd · Biotechnology, Health Care, Health Diagnostics, Therapeutics
- Lifesenz Cancer Research Labs Private Limited · Biotechnology, Health Care, Health Diagnostics, Therapeutics
- Oxford Brain Diagnostics · Biotechnology, Health Care, Health Diagnostics, Therapeutics
- Creatv MicroTech · Biotechnology, Health Care, Health Diagnostics, Therapeutics
About bioAffinity Technologies: questions and answers
What does bioAffinity Technologies do?
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) b
Where is bioAffinity Technologies headquartered?
bioAffinity Technologies is headquartered in San Antonio, Texas, United States.
How many employees does bioAffinity Technologies have?
bioAffinity Technologies has about 34 employees.
Has bioAffinity Technologies raised funding?
Yes. Fundz has recorded 5 funding events for bioAffinity Technologies. The most recent, Post-IPO Equity of $4.0M, was in Aug 2026.
Who leads bioAffinity Technologies?
Maria Zannes is a Chief Executive Officer, President and Director at bioAffinity Technologies.
What is the latest news on bioAffinity Technologies?
On Oct 15, 2026, SEC 8-K (8.01): On October 15, 2026, bioAffinity Technologies, Inc. announced through a press release that it will sponsor a Learning Theater presentation at CHEST 2026, focusing on the role of its product CyPath Lung® in lung cancer risk stratification and managing pulmonary nodules for high-risk p
Is bioAffinity Technologies a public company?
Yes. bioAffinity Technologies is publicly traded under the ticker BIAF.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy